4iml
From Proteopedia
(Difference between revisions)
(New page: '''Unreleased structure''' The entry 4iml is ON HOLD Authors: Fenn, S., Schiller, C., Griese, J., Hopfner, K.-P., Kettenberger, H. Description: CrossFab binding to human Angiopoietin 2) |
|||
| (8 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==CrossFab binding to human Angiopoietin 2== | |
| + | <StructureSection load='4iml' size='340' side='right'caption='[[4iml]], [[Resolution|resolution]] 2.93Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4iml]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4IML OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4IML FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.931Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4iml FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4iml OCA], [https://pdbe.org/4iml PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4iml RCSB], [https://www.ebi.ac.uk/pdbsum/4iml PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4iml ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action. There is a wide variety of design alternatives for such bispecific antibodies, including the "CrossMab" format. CrossMabs contain a domain crossover in one of the antigen-binding (Fab) parts, together with the "knobs-and-holes" approach, to enforce the correct assembly of four different polypeptide chains into an IgG-like bispecific antibody. We determined the crystal structure of a hAng-2-binding Fab in its crossed and uncrossed form and show that CH1-CL-domain crossover does not induce significant perturbations of the structure and has no detectable influence on target binding. | ||
| - | + | Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain.,Fenn S, Schiller CB, Griese JJ, Duerr H, Imhof-Jung S, Gassner C, Moelleken J, Regula JT, Schaefer W, Thomas M, Klein C, Hopfner KP, Kettenberger H PLoS One. 2013 Apr 17;8(4):e61953. doi: 10.1371/journal.pone.0061953. Print 2013. PMID:23613981<ref>PMID:23613981</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| + | </div> | ||
| + | <div class="pdbe-citations 4iml" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Fenn S]] | ||
| + | [[Category: Griese J]] | ||
| + | [[Category: Hopfner K-P]] | ||
| + | [[Category: Kettenberger H]] | ||
| + | [[Category: Schiller C]] | ||
Current revision
CrossFab binding to human Angiopoietin 2
| |||||||||||
